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S U M M A R Y
Objective: In this study we sought to assess the efﬁcacy of a technetium-99m (Tc-99m)-labeled third-
generation cephalosporin as an infection imaging agent in the accurate detection of the sites of bacterial
infection in vivo.
Design: Ceftriaxone (CRO) was formulated into a ready-to-use single-vial cold kit with a shelf-life of over
6 months and was successfully labeled with technetium. The radiolabeled drug, Tc-99m-CRO, was
subjected to the following preclinical evaluations: radiochemical purity, in vitro and in vivo stability,
bacterial binding assay, and pharmacokinetic studies in animals and in human patients.
Results: The kit formulation exhibited excellent radiolabeling efﬁciency (99%) and high in vitro and in
vivo stability. The radiolabeled drug exhibited slow blood clearance (12% at 4 h), and the high protein
binding and excretion pattern of the labeled formulation mimics the reported pharmacokinetic proﬁle of
the drug alone. In the animal model, scintigraphy scans showed higher uptake of the radiopharmaceuti-
cal in infectious lesions, even at 1 h post-administration, in comparison to inﬂammatory lesions. The
clinical evaluation of Tc-99m-labeled CRO showed a diagnostic accuracy of 83.3%, and a sensitivity and
speciﬁcity of 85.2% and 77.8%, respectively.
Conclusions: This kit formulation has the potential for imaging bacterial infections with much higher
sensitivity and speciﬁcity as compared to other Tc-99m-labeled antibiotics available as convenient
ready-to-use kits in routine clinical practice.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The detection of any infection by nuclear medicine techniques
relies on the physiological and biochemical changes that occur at
the site of the lesion, which appear much earlier than anatomical
changes.1–3 Single photon emission computed tomography
(SPECT), a nuclear medicine technique that can be used in clinics,
gives a more detailed localization of the lesion and can provide
crucial information, especially in patients with osteomyelitis and
those suspected of deep-seated infections of joint prostheses or
implants. The most widely used radioisotope for this technique is
technetium-99m (Tc-99m) due to its favorable physical proper-
ties; the 140 keV energy of gamma emission and half-life of 6 h
offers ideal nuclear medicine imaging properties. Therefore a Tc-
99m radioisotope tagged to a biomolecule or small organic* Corresponding authors. Tel.: +91 11 23905117; fax: +91 11 23919509.
E-mail address: akmishra63@gmail.com (A.K. Mishra).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.10.011molecule of interest has the potential to make an ideal
radiopharmaceutical for diagnosis.4
Most radiopharmaceuticals reported in the literature for the
diagnosis of infection, such as radiolabeled polyclonal or mono-
clonal immunoglobulins, cytokines, peptides, and liposomes, are in
fact only tracers of the inﬂammation process.5–7 Certain radio-
pharmaceuticals that speciﬁcally bind to a variety of bacteria, such
as radiolabeled antibiotics, have been shown to detect and locate
infection, but have not shown a high speciﬁcity to discriminate
between bacterial infection and sterile inﬂammation.8–14 The ﬁrst
such radiopharmaceutical proposed was a two-vial kit of
ciproﬂoxacin tagged with Tc-99m (Infecton1), which was further
modiﬁed to a single-vial instant kit. However, bottlenecks in the
use of the kit such as the need for ﬁltration during reconstitution
caused additional radiation burden and led to the loss of
radioactivity.15–17
Looking at the need for a better infection imaging
formulation with higher speciﬁcity towards bacteria, we
labeled ceftriaxone (CRO) (Figure 1a), a third-generationses. Published by Elsevier Ltd. All rights reserved.
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therapeutic index because this basic unit of the cell wall
structure is not found in eukaryotic cells. The unique
mechanism of action of cephalosporins in which the penicillin
disrupts the ratio between penicillin-binding protein (PBP)-
mediated peptidoglycan synthesis and murein hydrolase
activity, results in autolysis of the cell wall structure. CRO is
a broad-spectrum semi-synthetic cephalosporin with a long
half-life and in vitro activity against staphylococci and Gram-
negative aerobic bacilli except for Pseudomonas.18 Structure–
activity relationship (SAR) studies of CRO show that the
presence of the 3-thiotriazine ring augments metabolic
stability and protein binding, thereby increasing its circulation
time, while its 7-aminothiadiazole alkoxy imine group ensures
extended beta-lactamase stability and enhanced anti-staphy-
lococcal activity.19
A current biomedical challenge is the detection and identiﬁca-
tion of orthopedic bacterial infections, because clinical cases that
are detected by culture positivity may only represent a small
fraction of infecting microbes, and identifying the causative
species and its sensitivity to a particular antibiotic is critical for
effective antimicrobial therapy. Therefore, any diagnostic test will
need to be proven useful and cost-effective in everyday clinical
practice by virtue of its sensitivity and speciﬁcity.
The objective of the present work was the development of a
biologically active Tc-99m-CRO single-vial kit formulation, which
can be easily reconstituted, to identify active septic foci in the
experimental model of Staphylococcus aureus-induced infectious
lesions in the rabbit, with further application in clinics after
approval from the human ethics committee.
2. Methods
2.1. Chemicals
Ceftriaxone was procured from Ranbaxy Industries Ltd and Tc-
99m-pertechnetate was supplied by BRIT, Regional Center, Delhi.
Stannous tartrate and gentisic acid were procured from Sigma
Aldrich. All other chemicals used were obtained from major
suppliers. A Capintec Caprac-R1 gamma scintillation well-type
counter was used for the determination of activity. The Inﬁnia
Hawkeye1GE gamma scintillation camera was used for imaging of
animals. Clinical patient imaging was done using Siemens
Biograph1 and E.Cam1 systems.
2.2. Radiolabeling with Tc-99m using a ready-to-use single-vial cold
kit of ceftriaxone
A lyophilized single-vial kit containing 2.5 mg of the sodium
salt of CRO, 200 mg of stannous tartrate, and 200 mg of gentisic acid
at appropriate pH was developed in-house. The kit was recon-
stituted by adding 1–2 ml of sterile Tc-99m-pertechnetate (74–
740 MBq) to the lyophilized vial with continuous mixing. The
reaction mixture was incubated at room temperature for 30 min.
2.3. Radiochemical purity
The radiochemical purity of Tc-99m-CRO was assessed by
ascending instant thin-layer chromatography (ITLC) using silica
gel-coated ﬁber glass sheets (Pall Corporation) and two solvent
systems, namely (1) 100% acetone and (2) a solvent mixture of
ethanol, ammonia, and water (2:1:5 v/v), as mobile phases. The
radioactive contaminants were identiﬁed as reduced/hydrolyzed
(R/H) Tc-99m (Rf = 0.0) and free Tc-99m-pertechnetate (Rf = 1.0)
and the labeled product remained at the point of application when
100% acetone alone was used as the mobile phase. The labeledproducts moved with the solvent front (Rf = 1.0) along with free Tc-
99m-pertechnetate, leaving R/H Tc-99m at the origin (Rf = 0.0)
when the solvent mixture was used as mobile phase. This was
further conﬁrmed by chromatographic analysis by scanning the
developed TLC plate in an EZ TLC scanner.
2.4. Lyophilization and stability of the ceftriaxone kit formulation
The samples were subjected to lyophilization using a Triad
laboratory freeze-dryer. Pre-freezing of the kit was carried out at a
temperature of 40 8C for 7.5 h. The temperature was subsequent-
ly increased to 10 8C at 0.6 8C/min for primary drying for 5 h.
Further ramping of the temperature by 0.25 8C/min was done with
the temperature increasing to 20 8C and the chamber pressure
maintained at 0.03 mbar for 15 h. The stability of the ready-to-use
kit (n = 6) was determined at 7, 14, 30, 60, 90, and 180 days after
storage under the following conditions: (1) in a freezer at 20 8C
with and without nitrogen atmosphere, (2) in a refrigerator at 4 8C,
and (3) at room temperature (25 8C).
2.5. In vitro stability study
The radiolabels of the drug were tested for in vitro stability by
ascending ITLC. For in vitro stability in physiological saline and
serum, 100 ml of the radiolabel was mixed with 2 ml each of 0.9%
saline and serum. ITLC was carried out to assess the efﬁciency of
labeling after incubation at 37 8C for 30 min.
2.6. Microorganisms
Overnight cultures of S. aureus bacteria were prepared on
tryptone soya agar (Oxoid) plates at 32 8C. Aliquots of suspensions
of harvested microorganisms containing 2  108 colony-forming
units (CFU) were kept in 1 ml of buffered peptone water (Oxoid) at
4 8C for a maximum of 1 week.
2.7. Bacterial binding assay
Bacterial binding of Tc-99m-CRO was assessed with both living
and heat-killed S. aureus bacteria. Four groups of bacteria were
deﬁned and used in sets of six vials: group A was the blank control
group, groups B and D consisted of live bacteria, and group C
consisted of heat-killed bacteria. The radiotracer for the study was
prepared with a ﬁnal concentration of 30 mg/ml of CRO and
600 mg/ml of diethylenetriamine pentaacetate (DTPA).
A bacterial suspension (0.9 ml) containing approximately
108 CFU was taken, and exactly 0.1 ml of phosphate-buffered
saline (PBS) containing approximately 5 MBq of radiolabel was
added to the test tube. The mixture was incubated for 1 h at
37 8C and then centrifuged for 5 min at 2000 rpm at a
temperature of 4 8C; the pellet was then resuspended in 1 ml
ice-cooled PBS. The resuspended pellet was then centrifuged
again for 5 min, the supernatant separated and 1 ml of ice-
cooled PBS added.
The supernatant was removed and the activity in the bacterial
pellet was determined using the gamma counter. The radioactivity
in the bacterial pellet was expressed as the percentage of the Tc-
99m activity bound to bacteria with regard to total Tc-99m
activity.
2.8. Statistical analyses
All mean values were expressed as the percentage of the
injected dose per gram or ratio  standard deviation (SD). A
statistical analysis was performed of the clinical outcomes from the
two imaging centers using the Student’s t-test.
Figure 1. Chemdraw1 structures of (a) ceftriaxone and (b) proposed binding of ceftriaxone with Tc-99m.
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All animal experiments were carried out in accordance with the
guidelines of the INMAS Animal Ethics Committee. Mice weighing
15–25 g of BALB/c strain were used for the biodistribution studies.
New Zealand albino rabbits weighing 2.5–3.0 kg were used for the
blood clearance studies, serum protein binding study, and gamma
scintigraphy. The animals were taken at random from the stock
colony and used from the experimental animal facility at the
institute. The animals were fed laboratory chow pellets and had
free access to food and water. The animals were in a room with
light during the daytime and no light from 19:00 h in the evening
until morning; the temperature was maintained at approximately
25 8C.
2.10. Blood clearance study
Tc-99m-CRO (74 MBq/0.1 ml) was administered to rabbits (n =
3) through the ear vein, and blood samples were collected at
different time intervals post-administration. The radioactivity in
blood samples was measured in a well-type gamma counter and
was calculated as the percentage of the injected dose.2.11. In vitro and in vivo protein binding study
For the in vitro protein binding study, 37 MBq of Tc-99m-CRO in
0.1 ml was mixed with 2 ml of plasma (n = 6). Aliquots were taken
at various time intervals and proteins were precipitated by adding
equal volumes of 12.5% trichloroacetic acid (TCA) and plasma. The
radioactivity in the precipitate and supernatant was measured in a
well-type gamma counter. The plasma protein binding was
expressed as the fraction of total activity in the sample. For in
vivo studies, 74 MBq of radiotracer was administered to the rabbit
and blood samples were withdrawn at various time intervals. The
plasma was separated from the samples and was processed in the
same way as described above for the in vitro studies.
2.12. Biodistribution study in normal mice
The in vivo distribution of Tc-99m-CRO was studied in 2-month
old BALB/c mice (n = 3; each weighing approximately 22 g). An
aliquot of 100 ml of Tc-99m-CRO (3.7 MBq) was administered
intravenously (IV) to each mouse through the tail vein. The animals
were sacriﬁced at different time intervals and the different organs
were removed and collected into pre-weighed tubes. The
Figure 2. Radiochromatogram proﬁle of Tc-99m-labeled ceftriaxone.
Table 1
In vitro stability of Tc-99m-ceftriaxone
Incubation time (h) % Radioactivity
Free Tc-99m R/H Tc-99m Tc-99m-CRO
0 0.8 1.8 97.4
1 1.0 1.8 97.2
2 1.1 2.1 96.8
4 1.8 2.6 95.4
24 2.6 5.8 91.4
R/H, reduced/hydrolyzed; CRO, ceftriaxone.
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spectrometer and count per min (CPM) values were decay-
corrected; results were calculated as the percentage injected dose
per gram of wet tissue. All animal studies were approved by the
local experimental animal ethics committee and performed in
accordance with their guidelines.
2.13. Experimental animal models
Induction of sterile inﬂammation: 100 ml of sterile turpentine
oil was injected deep into the left forearm of New Zealand albino
white rabbits (n = 3) 2 days before scintigraphy studies.
Induction of bacterial infection: a bacterial suspension of S.
aureus (concentration 107 CFU/100 ml) was injected deep into the
left forearm of New Zealand albino white rabbits (n = 3) 24 h before
the imaging study.
2.14. Experimental animal model scintigraphy
Scintigraphy in rabbits was carried out after IV administration
of 0.1 ml of Tc-99m-CRO (74 MBq) through the ear vein. The
animals were anesthetized by intramuscular injection of ketamine
hydrochloride (50 mg/kg body weight) 10 min before imaging. The
animal was ﬁxed on a board in the posterior anterior position and
imaging was performed using a planar gamma camera (GE
Hawkeye1) at 1, 4, and 24 h post-administration. Regions of
interest (ROIs) were drawn around the infectious/inﬂammatory
focus and over the contralateral control zone for comparison, and
analyzed using Entegra1 software (Elgems, Haifa, Israel).
2.15. Preliminary clinical studies
All clinical studies were carried out in accordance with the
guidelines of the institutional ethics committee. Patients who were
on any antibiotic treatment, who had undergone a recent
amputation/debridement, or who had a documented hypersensi-
tivity to cephalosporins were excluded from the study. Written
and informed consent was obtained from all the patients. The
purpose of the study was explained to each study participant.
Thirty-six patients (22 male and 14 female; mean age 47.44
years, range 18–78 years) with a clinical and radiological suspicion
of an orthopedic infection were recruited. All the patients
underwent a 3-phase bone scan (740 MBq, Tc-99m-methylene
diphosphonate (MDP), IV injection) followed 4 days later by Tc-
99m-CRO scanning (static/isotime images at 1, 4, and 24 h after IV
administration of 555.0 MBq activity of the radiotracer). Whole
body Tc-99m-CRO scanning was also done to study the biodis-
tribution of the radiotracer. Sample aspirates from the site
involved were taken and analyzed for microbial growth. A
representative case, an 18-year-old male patient, presented with
pain, swelling, and a non-healing ulcer with active pus discharge
on the right leg (distal part medially) of 2-month duration;
microbial culture of a wound swab grew S. aureus.
3. Results
The optimum labeling yield (99%) was achieved when 200 mg
stannous tartrate was used in the presence of gentisic acid for
complexing 2.5 mg CRO with 74–740 MBq of Tc-99m-pertechne-
tate. Quality control tests using ITLC revealed that Tc-99m-CRO
contained less than 1% free Tc-99m-pertechnetate and 2–3% R/H
Tc-99m. When the preparation was stored at room temperature,
there was no signiﬁcant degradation of the product up to 4 h. The
proposed structure of the 1:1 complexation of Tc-99m with CRO
drug is shown in Figure 1b. Radiochemical purity was further
assessed through EZ TLC scanner, and the radiochromatogramshowed the Rf of the labeled CRO to be 0.9, while free technetium
was found along with the solvent front (Figure 2). Even after 24 h of
storing the preparation at room temperature, more than 95% of
radioactivity was found to be coupled with CRO. Since the
radiolabeled drug remains in the complexed form (above 90%)
up to 24 h, it appears to be a suitable candidate for diagnostic
imaging. Also, considering the decay factor and the biological half-
life of 8 h during which almost all the bound complex is excreted
from the body, it will not cause any additional radiation burden to
the patient.
On incubation with normal saline and rabbit serum, the
radiolabel was found to be stable up to 24 h. However, at 24 h
the in vitro stability was reduced, as 5–6% free Tc-99m-
pertechnetate was found in the preparation (Table 1).
Lyophilization of the kit was efﬁciently and successfully carried
out using our protocol, and a ﬂuffy off-whitish lyophilized powder
was obtained. Storage of the kit was studied in three different
temperature conditions. The shelf-life of the refrigerated lyophi-
lized kit was found to be more than 6 months and the results
showed no signiﬁcant differences in stability of the kit at 4 8C and
at 20 8C, while there was a difference for storage at room
temperature. Hence, for optimal labeling efﬁciency, the formulated
kit should be stored in a refrigerator at 4 8C.
Following S. aureus incubation at 37 8C for the bacterial binding
assay, results showed that the binding of labeled CRO to heat-killed
bacteria and live bacteria was similar, while a signiﬁcantly lower
fraction of bacterial binding was found in the case of labeled DTPA
as compared to the labeled drug (Table 2).
Blood clearance of Tc-99m-CRO in whole blood with time after
IV administration in rabbits exhibited bi-exponential clearance
with 12% of the radioactivity in blood circulation at 4 h (Figure 3).
In vitro as well as in vivo protein binding studies showed that Tc-
99m-CRO was highly protein-bound (92% at 4 h) (Figure 4). The
biodistribution of Tc-99m-CRO in the various organs of mice at
various time intervals post-administration is shown in Table 3.
Among all the organs studied, the kidneys showed a maximum
uptake of 12.2% of the injected dose per whole organ at 1 h, which
increased to 15.8% at 4 h. Signiﬁcant radioactivity in the liver,
Table 2
Percentage bacterial binding after incubation with Tc-99m-ceftriaxone in groups B
and C, and with Tc-99m-diethylenetriamine pentaacetate in group D ( SD of six
vials in each group)
Group % binding
Live-bacteria (group B), Tc-99m-CRO 4.35  1.16
Heat-killed bacteria (group C), Tc-99m-CRO 3.31  0.86
Live-bacteria (group D), Tc-99m-DTPA 0.49  0.22
CRO, ceftriaxone; DTPA, diethylenetriamine pentaacetate.
Figure 4. In vitro and in vivo plasma protein binding of Tc-99m-ceftriaxone
expressed as a fraction of total radioactivity in the sample.
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hepatobiliary and renal routes.
Scintigraphy studies in animal models showed that the
uptake of the radiotracer was appreciably higher in the infected
muscle in comparison to the inﬂamed muscle (Figure 5). Tc-
99m-CRO showed only background activity in turpentine-
induced sterile inﬂammation, and activity detected at the site
was similar to that in the contralateral muscle area. In the case of
S. aureus-induced infection, Tc-99m-CRO had a very high target
to non-target ratio, which kept increasing, reaching a maximum
of 4.5 at 24 h (Table 4).
In this study we also evaluated the clinical utility of Tc-99m-
labeled CRO for the detection of orthopedic infections where scan
ﬁndings (CRO scan) were positive in 25/36 and culture was positive
in 27/36 patients (Table 5). The diagnostic accuracy of the
technique was found to be 83.3%, and the sensitivity and speciﬁcity
were 85.2% and 77.8%, respectively. The results presented are the
cumulative data from two different imaging centers. A statistical
analysis was performed using the Student’s t-test and conﬁrmed
that there was no statistical difference with respect to outcome
between the two centers.
The radiolabeled kit showed encouraging results in localizing
orthopedic infections, especially in the setting of acute bacterial
infection (Figure 6). The representative scan shows a high target to
non-target ratio at 1 h post-injection in the patient with an active
bacterial infectious lesion on the right leg, which was conﬁrmed
through microbial culture.
4. Discussion
The design of an ideal infection imaging radiopharmaceutical
requires the optimization of several factors: (1) high speciﬁcity in
vivo/target to non-target ratio, (2) non-immunogenic, (3) low
toxicity, (4) cost-effective, (5) easy to prepare, and (6) widely
available.20 This kit was formulated keeping in mind that the long
shelf life of the kit preparation and simple convenient method toFigure 3. Blood clearance study of Tc-99m-ceftriaxone in rabbits (average data of
three rabbits).
Figure 5. Whole body scintigraphy of experimental models of sterile inﬂammation
and septic lesions in rabbits, obtained at 1, 4, and 24 h post IV administration of 74
MBq of Tc-99m-ceftriaxone. Sterile inﬂammation at (a) 1 h, (c) 4 h, and (e) 24 h;
septic lesions at (b) 1 h, (d) 4 h, and (f) 24 h. For image (c), the oval represents the
inﬂammation site, while in the case of image (d), the left oval represents the
infectious lesion and the right oval represents the contralateral side (control).
Table 3
Tissue distribution in normal mice at 1, 4, and 24 h after intravenous administration
of 100 ml of Tc-99m-ceftriaxone (40 kBq). Data expressed as percent injected dose
per whole organ  SD of three animals
Organ Percent injected dose/whole organ
1 h 4 h 24 h
Blood 14.20  2.1 10.2  0.87 4.9  0.20
Heart 1.22  0.03 0.6  0.04 0.3  0.01
Lungs 2.80  0.04 1.5  0.08 0.4  0.01
Liver 8.6  0.80 14.8  1.16 5.2  0.52
Kidneys 12.2  1.00 15.8  1.22 12.6  1.56
Intestines 2.32  1.36 15.38  2.32 18.2  4.28
Stomach 0.4  0.10 0.8  0.30 0.5  0.21
Table 4
Target to non-target ratio of Tc-99m-ceftriaxone in animal models of sterile
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available in the nuclear medicine ﬁeld.
The idea here was to label an antibiotic and thereby enable the
accurate diagnosis of microorganisms at the site of infection in the
routine clinical setting. The approach with Tc-99m-labeled
ciproﬂoxacin has shown considerable promise in preliminary
studies, but other studies in animal models and in clinics have
shown the ciproﬂoxacin tracer to disappear from the site of
infection as well as from inﬂammation with equal rapidity.21–23
Recently, we successfully formulated an isoniazid antibiotic
derivative as a radiolabeled agent for detecting tubercular
infectious lesions.24 In this study CRO was chosen, which is a
third-generation cephalosporin antibiotic with a broad spectrum
of activity against Gram-positive and Gram-negative bacteria and
especially excellent activity with a low minimum inhibitory
concentration (MIC) against all the strains of S. aureus.25 ThisTable 5
Clinical data for the ceftriaxone for infection imaging kit used in 36 patientsa
Patient No. Age Sex Tc-99m-MDP scan 
1 21 F + 
2 62 M + 
3 37 M + 
4 48 F + 
5 51 F + 
6 60 M + 
7 23 M + 
8 40 F + 
9 39 F + 
10 18 M + 
11 33 M + 
12 27 M + 
13 51 F + 
14 33 F + 
15 42 M + 
16 61 M + 
17 45 F + 
18 78 F + 
19 24 M + 
20 71 M  
21 70 M + 
22 66 M + 
23 63 M + 
24 59 M + 
25 38 M + 
26 65 F + 
27 49 M + 
28 44 M + 
29 19 M + 
30 70 F + 
31 68 M + 
32 70 M + 
33 52 F + 
34 35 F + 
35 52 F + 
36 24 M + 
MDP, methylene diphosphonate; CRO, ceftriaxone; F, female; M, male; TB, tuberculosi
a Sensitivity 85.2%; speciﬁcity 77.8%; positive predictive value 92.0%; negative prediantibiotic acts by binding to the bacterial wall, inhibiting the
synthesis of peptidoglycan (absent in eukaryotes), and inhibiting
the synthesis of the bacterial wall leading to bacterial death.26
Moreover, it contains various groups (Figure 1b) to link to a
radioisotope such as the extensively used technetium.27
The results obtained in this study show that CRO was
successfully labeled with Tc-99m with a high radiochemical yield
(Table 1). During labeling of ciproﬂoxacin, a good amount of R/H
Tc-99m is formed, which requires ﬁltration of the preparation
before use, as documented in the literature.28 In contrast, Tc-99m-
CRO required no such ﬁltration as it contained negligible R/H Tc-
99m. The duration and temperature of storage did not show any
difference in the labeling yield of the kit, which is a further beneﬁt
of this single-vial kit preparation in the nuclear medicine setting in
the hospital. The radiotracer exhibited good in vitro and in vivo
stability, and a slow release (approximately 6–8%) of Tc-99m-
pertechnetate was observed up to 24 h.
The distribution of Tc-99m-CRO showed 90% protein binding,
which is in line with reported data.29 The normal Tc-99m-CRO
image showed high uptake by the kidneys and in bile, with
moderate uptake by the liver and spleen. No uptake by bone, bone
marrow, or other soft tissues was observed, and Tc-99m-CRO
predominantly showed high blood pool activity. The gall bladder
could be seen occasionally, and some bowel activity occurred in
the delayed images, which is an important observation in
biodistribution studies. The high protein binding explains the
higher activity in the blood pool. The radiolabeled CRO followed
the same pharmacokinetic proﬁle as the unlabeled antibiotic,






































ctive value 63.6%; diagnostic accuracy 83.3%.
Figure 6. Representative multimodality scan showing a non-healing ulcerative lesion in the right leg of an 18-year-old patient with a positive microbial culture report. (a)
SPECT image; (b) functional image, coronal slice; (c) computed tomography image, coronal slice showing bone destruction; (d) multimodality fusion of SPECT and computed
tomography images documenting the bone and soft tissue infection.
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stability of the radiolabel throughout the duration of the study.
The qualitative scintigraphy evaluation of the radiolabel
suggests that the nonspeciﬁc uptake of Tc-99m-CRO did not occur
at any time point (1, 4, and 24 h) in the case of sterile inﬂammation.
In the quantitative ROI analysis of the radiolabeled antibiotic, there
was increased uptake of radioactivity and a signiﬁcantly high
target to non-target ratio at the infectious lesion when studied up
to 24 h (Table 4). There are several factors that may account for this
observation. SAR studies in a series of ﬂuoroquinolones showed
that the probable reason for the absence of speciﬁcity of
ciproﬂoxacin to staphylococcal infections lies in its structure,
which lacks a p-substituted derivative with electron donor
properties at the 7-pyyrolidinyl ring for better potency against
Staphylococcus.30 However, the presence of the 3-thiotriazine ring
in the CRO molecule augments metabolic stability and protein
binding, thereby increasing its circulation time, while its 7-
aminothiadiazole alkoxy imine group ensures extended beta-
lactamase stability and enhanced anti-staphylococcal activity.31
The interaction of Tc-99m-ciproﬂoxacin with various physiological
factors prior to its interaction with the bacterial chromosomes32
and its lesser protein binding (30%) causes reduced availability in
the blood pool. Meanwhile, in the case of Tc-99m-CRO, high
protein binding results in the increased availability of circulating
drug and consequently it continues to accumulate at the site of
infection.
The successful imaging of bacterial infection in our study stems
from a combination of the direct binding of Tc-99m-CRO to
dividing bacteria and the dynamic speciﬁcity that occurs when
uptake caused by bacterial infection persists and increases with
time. Therefore, the results conﬁrm our proposition that Tc-99m-
CRO could in fact distinguish aseptic from septic inﬂammatory
processes. We successfully extended its use to the imaging of
bacterial infections in human subjects after receiving approval
from the human ethics committee.33 Biodistribution studies in
human subjects indicated that two-thirds of the radiotracer was
excreted through the renal route and a third through the
hepatobiliary route, which corroborates the experimental animal
studies performed using this preparation and the in vivo behaviorof the antibiotic in the product monograph of the drug itself. Also,
when used in some of the patients with clinical and bone
scintigraphy evidence of microbial infection, especially in cases of
bacteria-induced osteomyelitis,34 the results showed a progressive
increase in radiolabeled antibiotic uptake in the involved site, with
a high target to non-target ratio at 1 and 4 h post-injection.
The single-vial kit preparation of Tc-99m-CRO has reasonably
good accuracy in the clinical diagnosis of orthopedic infections
(Figure 6). The use of this formulation is being further validated in a
large number of patients and also in a few treated cases of
osteomyelitis.
In conclusion, the formulated kit is handy to use and has the
potential to improve the early detection and treatment of a wide
variety of deep-seated bacterial infections. It also has the ability to
localize infective foci accurately, which is important for surgical
interventions such as the drainage of abscesses. In addition, serial
imaging with Tc-99m-CRO might be useful for monitoring the
clinical response to treatment and for optimizing the duration of
antimicrobial treatment.
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